Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation [1]

Bone Marrow Transplantation

Volumn 40, Issue 2, 2007, Pages 175-177

  Meniane, J C ^a   El Cheikh, J ^a   Faucher, C ^a   Furst S ^a   Bouabdallah, R ^a   Blaise, D ^a   Mohty, M ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG WITHDRAWAL; FOLLOW UP; HLA MATCHING; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KARNOFSKY PERFORMANCE STATUS; LETTER; LONG TERM CARE; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

GRAFT VS TUMOR EFFECT; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 34447287326     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705702     Document Type: Letter

References (9)

1. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107: 3442-3446.
2. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5: 273-277.
3. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N et al. Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 2003; 30: 291-296.
4. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2001; 27: 1027-1029.
5. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.
6. Levy V, Morel P, Porcher R, Chevret S, Wattel E, Leblond V. Advanced Waldenstrom's macroglobulinemia: Usefulness of Morel's scoring system in establishing prognosis. Haematologica 2005; 90: 279-281.
7. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001; 28: 609-611.
8. Martino R, Shah A, Romero P, Brunet S, Sierra J, Domingo-Albos A et al. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 23: 747-749.
9. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom's macroglobulinaemia. Br J Haematol 2006; 133: 158-164.